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Background: Thrombolysis remains an important reperfusion strategy for eligible patients with acute ST-segment elevation myocardial infarction 
(STEMI). Intracranial bleeding is a potentially fatal complication.
Methods: A total of 342 Patients who received thrombolytic therapy in a University Hospital in Hong Kong for management of STEMI from 2001 
to 2010 were analyzed. Cases were identified through Hospital Pharmacy, Hospital Authority Clinical Management System and AMI Clinical Pathway. 
Data were analyzed using SPSS 16.0.
Results: 266 patients (77.78%) and 76 patients (22.22%) were given Streptokinase and Fibrin-specific agents (TNK-tPA/Alteplase) respectively. 
The overall rate of intracranial haemorrhage was 1.46% (5 out of 342). The rate of intracranial haemorrhage of Fibrin-specific agents (TNK-tPA/
Alteplase) and Streptokinase was 5.26% (4 of 76) and 0.38% (1 of 266) respectively (p=0.002 Odds Ratio 14.71). Rate of intracranial haemorrhage 
was significantly higher in patients with admission systolic blood pressure≥160mmHg (p=0.043 Odds ratio 5.33). Higher rates of intracranial 
haemorrhage were observed in sub-groups of Age≥75, Female, History of Stroke/Transient Ischaemic Attack (p=0.114, 0.266, 0.155 respectively). 
Streptokinase was associated with more adverse events (34.96%) at time of thrombolytic administration which included hypotension, bradycardia 
and allergic reactions (p=0.000). The success rate of reperfusion was higher with TNK-tPA (78.67%) compared to Streptokinase (71.97%), but not 
statistically significant (p=0.246).
Conclusion: This study showed the reperfusion rate after thrombolysis in STEMI was only marginally better by Fibrin-specific agents (TNK-tPA/
Alteplase) than by Streptokinase. The rate of intracranial haemorrhage, however, was much higher statistically with Fibrin-specific agents. These 
findings warrant extreme caution to be taken when selecting thrombolytic agents in Chinese patients with STEMI. In patients with potentially high 
bleeding risk (high admission systolic blood pressure, age≥75, female, history of stroke/transient ischaemic attack), primary percutaneous coronary 
intervention should be considered.
